Navigation Links
Yongye Biotechnology to Present at Roth Conference
Date:2/9/2009

BEIJING, Feb. 9 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals, located in the People's Republic of China, today announced that the Company's management will present at the upcoming Roth 21st Annual OC Growth Stock Conference in Dana Point, California.

The date, time, presenters, and location of Yongye Biotechnology International, Inc.'s presentation at the conference are as follows:

    Date:           Wednesday, February 18, 2009
    Time:           11:30 a.m. Pacific Time
    Presenters:     Mr. Zishen Wu, Chairman and CEO;
                    Mr. Larry Gilmore, Vice President of Corporate Strategy
    Venue:          Track 5
                    The Ritz Carlton Laguna Niguel
                    One Ritz-Carlton Drive
                    Dana Point, California 92629

The ROTH 21st Annual OC Growth Stock Conference will feature presentations from over 200 growth companies. This event is designed to provide investors with a unique opportunity to gain insight into leading companies across all sectors. Additionally, there will be a special track dedicated to companies based in China. Presentations will provide a brief overview of the company's operations, and speakers will spend the majority of their time discussing topics that will highlight the value and investment opportunity their company represents.

The Company will be available to meet with analysts and investors during the conference. Interested parties and investors may find more information about the conference by contacting conference@roth.com or calling (800) 933-6830.

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the research and development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Safe Harbor Statement

This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Yongye Biotechnology International, Inc.
     Mr. Larry Gilmore-VP of Corporate Strategy
     Phone: +86-8232-8866 x8880
     Email: larry.gilmore@gmail.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Announces Record Third Quarter Results
2. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
3. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
4. Yongye Biotechnology International Raises $9.4 Million in Private Placement
5. Yongye Biotechnology International Announces Second Quarter Results
6. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
7. Yongye Biotechnology International Retains CCG Investor Relations
8. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
9. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
10. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
11. Energy, Biotechnology and Agribusiness Veterans Form SG Biofuels to Develop Jatropha as Low-Cost, Sustainable Oil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Ben Franklin Technology Partners of Southeastern Pennsylvania ... ("IHG"), the parent company of Independence Blue Cross; and ... announced their intentions for a $6 million funding initiative ... healthcare startups. Responding to a burgeoning economic ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
Breaking Biology Technology:
(Date:12/7/2016)...   Veridium , a leader in biometrics-based ... CEO James Stickland . Stickland, a seasoned ... has served in senior executive roles for HSBC, ... expanding a pipeline of venture capital and accelerating ... served as managing director of U.K.-based fintech firm ...
(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
Breaking Biology News(10 mins):